Table III.
Clinical information and anti-CK8/18 reactivity in breast cancer patients.
| Category | No. of patients | anti-CK8/18 n (%) | CA15-3 n (%) | ||
|---|---|---|---|---|---|
| < | > cutoff | < | >10 | ||
| Age (years) | |||||
| ≤50 | 13 | 8 (62) | 5 (38) | 10 (77) | 3 (23) |
| >50 | 17 | 8 (47) | 9 (53) | 11 (65) | 6 (35) |
| Stage | |||||
| 0 | 2 | 1 (50) | 1 (50) | 1 (50) | 1 (50) |
| I | 10 | 5 (50) | 5 (50) | 8 (80) | 2 (20) |
| IIA | 7 | 4 (57) | 3 (43) | 5 (71) | 2 (29) |
| IIB | 8 | 4 (50) | 4 (50) | 6 (75) | 2 (25) |
| IIIA | 3 | 2 (67) | 1 (33) | 1 (33) | 2 (67) |
| Alkaline phosphatase (IU/l) | |||||
| ≤140 | 7 | 4 (57) | 1 (14) | 4 (57) | 1 (14) |
| >140 | 23 | 12 (52) | 11 (48) | 15 (65) | 8 (35) |
| CA15-3 (IU/l) | |||||
| ≤10 | 21 | 12 (57) | 9 (43) | - | - |
| >10 | 9 | 4 (44) | 5 (56) | - | - |
| Tumor size (cm) | |||||
| ≤2 | 9 | 4 (44) | 5 (56) | 7 (78) | 2 (22) |
| >2 | 21 | 12 (57) | 9 (43) | 15 (71) | 6 (29) |
| Pathology | |||||
| Invasive duct carcinoma | 22 | 13 (59) | 9 (41) | 15 (68) | 7 (32) |
| Othersa | 8 | 3 (38) | 5 (63) | 6 (75) | 2 (25) |
| Estrogen receptor status | |||||
| − | 6 | 4 (67) | 2 (33) | 5 (83) | 1 (17) |
| +/− | 3 | 0 (0) | 3 (100) | 2 (67) | 1 (33) |
| ++ | 6 | 4 (67) | 2 (33) | 6 (100) | 0 (0) |
| +++ | 14 | 8 (57) | 6 (43) | 7 (50) | 7 (50) |
| Progesterone receptor status | |||||
| − | 9 | 5 (56) | 4 (44) | 7 (78) | 2 (22) |
| + | 5 | 2 (40) | 3 (60) | 3 (60) | 2 (40) |
| ++ | 2 | 2 (100) | 0 (0) | 1 (50) | 1 (50) |
| +++ | 12 | 8 (67) | 4 (33) | 8 (67) | 4 (33) |
| p53 | |||||
| − | 5 | 1 (20) | 4 (80) | 3 (60) | 2 (40) |
| + | 15 | 11 (73) | 4 (27) | 13 (87) | 2 (13) |
| ++ | 2 | 2 (100) | 0 (0) | 1 (50) | 1 (50) |
| +++ | 5 | 2 (40) | 3 (60) | 3 (60) | 2 (40) |
| erbB-2 | |||||
| − | 20 | 11 (55) | 9 (45) | 14 (70) | 6 (30) |
| +++ | 8 | 5 (63) | 3 (38) | 6 (75) | 2 (25) |
a
Others, invasive lobular carcinoma, invasive mucinous carcinoma, medullary carcinoma.